I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Cantargia R&D Day on nadunolimab featuring Prof Van Cutsem and Dr Paz-Ares

To Webcast

CEO presentation AGM

To the presentation (In Swedish)

Presentation of Cantargia’s report for the first quarter of 2022

May 23rd, 10.00 AM CET

To Audiocast

Panel discussion business development

To Panel discussion

CEO Interview

To the interview (In Swedish)

CEO interview

To the interview (in Swedish)

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)
Press releases

2022-06-21 (R) Notice of extraordinary general meeting in Cantargia AB (publ)

2022-06-21 (R) Cantargia resolves on a fully covered rights issue of approximately SEK 250 million

2022-06-09 Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg
CEO Cantargia
Analysis

2022-06-08, Nordea analysis of Cantargia

2022-05-31, Edison analys av Cantargia

2022-05-24, Redeye comments on Cantargia's Q1 report 2022

2025-05-24, Edison analysis of Cantargia

Presentations

2022-06-02, Presentation, Redeye Growth Day

2022-05-23, Presentation, Cantargia Årsstämma

2022-05-23, Presentation, Cantargia Q1 Report

2022-05-19, Presentation, ABGSC Life Science Summit 2022

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2022 · Cantargia AB